FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1519377716> ?p ?o ?g. }

• W1519377716 abstract "The introduction of new therapies has opened new therapeutic hopes in the field of treating Chronic Lymphocytic Leukemia (CLL). CLL is extremely heterogeneous in its clinical course; some patients live for decades with no need for treatment, whereas others develop aggressive clinical course with a survival of less than 2-3 years. The decision to treat CLL patients should be guided by clinical staging, the presence of symptoms and disease activity (Diehl et al. 1999). Once the diagnosis of CLL has been made, the treating physician is faced with the decision of not only how to treat the patient, but when to initiate therapy. In general practice, newly diagnosed patients with asymptomatic early-stage disease (Rai 0, Binet A) are monitored without therapy until they have evidence of disease progression. Studies from the French Cooperative Group on CLL, (Dighiero et al. 1998) the Cancer and Leukemia Group B,(Shustik et al. 1988) the Spanish Group PETHEMA, (Montserrat et al. 1996) and the Medical Research Council (Catovsky et al. 1988) confirm that the use of alkylating agents in patients with early-stage disease does not prolong survival (Group. 1999). Patients at intermediate (I and II) or high-risk (III and IV) according to the modified Rai classification or Binet stage B or C usually require the initiation of treatment at presentation. Some of these patients (in particular Rai intermediate risk or Binet stage B) can still be monitored without therapy until they exhibit evidence of progressive or symptomatic disease. During the past decade there have been major advances in understanding the pathogenesis of the disease and more efficient treatments have been developed. CLL treatments have seen the transition from single-agent alkyator-based therapies to nucleoside analogs, combination chemotherapy, and recently to monoclonal antibodies (MAbs) and chemoimmunotherapy. The use of immunotherapy is emerging as an exciting modality with significant potential to advance the treatment of B-cell malignancies. In the field of lymphoproliferative diseases rituximab, followed by the anti-CD52 antibody alemtuzumab, has changed the therapeutic landscape of B-cell cancers, particularly in patients with non-Hodgkin’s lymphoma (NHL) with more recent indications in the setting of CLL (Cheson 2006). Novel therapies are being evaluated both in pre-clinical studies and in clinical trials. These treatments include new MAbs such as ofatumumab, GA101, veltuzumab, epratuzumab," @default.
• W1519377716 created "2016-06-24" @default.
• W1519377716 creator A5006793451 @default.
• W1519377716 creator A5067770954 @default.
• W1519377716 date "2012-02-10" @default.
• W1519377716 modified "2023-09-30" @default.
• W1519377716 title "Emerging Therapies in Chronic Lymphocytic Leukemia" @default.
• W1519377716 cites W122353466 @default.
• W1519377716 cites W1540689218 @default.
• W1519377716 cites W159651808 @default.
• W1519377716 cites W1689607850 @default.
• W1519377716 cites W1845495416 @default.
• W1519377716 cites W1915689252 @default.
• W1519377716 cites W1963571549 @default.
• W1519377716 cites W1988217711 @default.
• W1519377716 cites W1989589268 @default.
• W1519377716 cites W1991758119 @default.
• W1519377716 cites W1993986769 @default.
• W1519377716 cites W1995916528 @default.
• W1519377716 cites W2001850157 @default.
• W1519377716 cites W2005230107 @default.
• W1519377716 cites W2007007231 @default.
• W1519377716 cites W2010069980 @default.
• W1519377716 cites W2012721290 @default.
• W1519377716 cites W2013510617 @default.
• W1519377716 cites W2015120596 @default.
• W1519377716 cites W2016973656 @default.
• W1519377716 cites W2017898416 @default.
• W1519377716 cites W2020671967 @default.
• W1519377716 cites W2026805676 @default.
• W1519377716 cites W2040426470 @default.
• W1519377716 cites W2054409932 @default.
• W1519377716 cites W2063463053 @default.
• W1519377716 cites W2063915853 @default.
• W1519377716 cites W2065239231 @default.
• W1519377716 cites W2066371170 @default.
• W1519377716 cites W2069724524 @default.
• W1519377716 cites W2070193300 @default.
• W1519377716 cites W2072539551 @default.
• W1519377716 cites W2072620152 @default.
• W1519377716 cites W2073873436 @default.
• W1519377716 cites W2074077303 @default.
• W1519377716 cites W2077294419 @default.
• W1519377716 cites W2078249396 @default.
• W1519377716 cites W2078619764 @default.
• W1519377716 cites W2080352981 @default.
• W1519377716 cites W2085068039 @default.
• W1519377716 cites W2092975278 @default.
• W1519377716 cites W2099145932 @default.
• W1519377716 cites W2105044162 @default.
• W1519377716 cites W2107567250 @default.
• W1519377716 cites W2116248495 @default.
• W1519377716 cites W2117648265 @default.
• W1519377716 cites W2123880240 @default.
• W1519377716 cites W2125134816 @default.
• W1519377716 cites W2126422041 @default.
• W1519377716 cites W2126529136 @default.
• W1519377716 cites W2129041705 @default.
• W1519377716 cites W2134264204 @default.
• W1519377716 cites W2135551958 @default.
• W1519377716 cites W2135806859 @default.
• W1519377716 cites W2136242714 @default.
• W1519377716 cites W2139793858 @default.
• W1519377716 cites W2140606816 @default.
• W1519377716 cites W2141139539 @default.
• W1519377716 cites W2153334574 @default.
• W1519377716 cites W2159880472 @default.
• W1519377716 cites W2161926682 @default.
• W1519377716 cites W2163348695 @default.
• W1519377716 cites W2163460786 @default.
• W1519377716 cites W2164006259 @default.
• W1519377716 cites W2165831472 @default.
• W1519377716 cites W2168648203 @default.
• W1519377716 cites W2226417367 @default.
• W1519377716 cites W2240217657 @default.
• W1519377716 cites W2242746351 @default.
• W1519377716 cites W2275948481 @default.
• W1519377716 cites W2317888977 @default.
• W1519377716 cites W2326175431 @default.
• W1519377716 cites W2396454380 @default.
• W1519377716 cites W2426446588 @default.
• W1519377716 cites W2482668501 @default.
• W1519377716 cites W2499935326 @default.
• W1519377716 cites W2530849054 @default.
• W1519377716 cites W2551655900 @default.
• W1519377716 cites W2556217933 @default.
• W1519377716 cites W2589501638 @default.
• W1519377716 cites W2979637638 @default.
• W1519377716 cites W2991834586 @default.
• W1519377716 cites W33733012 @default.
• W1519377716 cites W61258569 @default.
• W1519377716 cites W2101252134 @default.
• W1519377716 doi "https://doi.org/10.5772/29403" @default.
• W1519377716 hasPublicationYear "2012" @default.
• W1519377716 type Work @default.
• W1519377716 sameAs 1519377716 @default.
• W1519377716 citedByCount "0" @default.
• W1519377716 crossrefType "book-chapter" @default.
• W1519377716 hasAuthorship W1519377716A5006793451 @default.
• W1519377716 hasAuthorship W1519377716A5067770954 @default.

• next